01-02-2017 | Erratum
Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
Published in: International Journal of Clinical Oncology | Issue 1/2017
Login to get access